CARMAT Reports Its FY 2021 Financial Results and Confirms Its 2022 Prospects
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CARMAT Reports Its 2021 Half-year Results and Issues an Update on Its Latest Progress and Main Strategic Objectives
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(0)
Regulatory News:
CARMAT (FR0010907956, ALCAR), the designer and developer of the world s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, informs its shareholders that the annual general meeting (AGM) of May 12, 2021 was able to deliberate, quorum having been reached.
Given the ongoing restrictions associated with the COVID-19 context, CARMAT s AGM was held behind closed doors and streamed online. This AGM approved all the resolutions tabled, with the exception of the 26
th resolution, which was rejected on the recommendation of the Board of Directors.
CARMAT : s Board of Directors is reorganising its governance and proposes the appointment of three new directors to support the new strategic phase of industrialization and commercialization
05/07/2021 | 01:01am EDT
Send by mail :
Message :
Required fields
The Board of Directors warmly thanks Dr. Philippe Pouletty, Managing Director of Truffle Capital, for his exceptional contribution to the development of the CARMAT project, and proposes the appointment of three new directors, Florent Battistella, David Coti and John B. Hernandez.
Regulatory News:
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announced today the reorganization of its governance with the proposed appointment of Florent Battistella, David Coti and John B. Hernandez as directors. These appointments will be